Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?

Journal of Neurology Neurosurgery and Psychiatry

Volumn 67, Issue 6, 1999, Pages 710-715

  Davie, C A ^a   Silver, N C ^a   Barker, G J ^a   Tofts, P S ^a   Thompson, A J ^a   McDonald, W I ^a   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

1H magnetic resonance spectroscopy; Magnetisation transfer; Multiple sclerosis; N acetyl aspartate

Indexed keywords

N ACETYLASPARTIC ACID;

ARTICLE; CENTRAL PONTINE MYELINOLYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; HUMAN; MAGNETISATION TRANSFER IMAGING; MULTIPLE SCLEROSIS; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 0032753301     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.67.6.710     Document Type: Article

References (40)

1. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992;18:319-34.
2. 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989; 13:23-31.
3. Urenjak J, Williams SR, Gadian DG, et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-9.
4. Scolding NJ, Rayner PJ, Sussman J, et al. A proliferative adult human oligodendrocyte progenitor. Neuroreport 1995;6:441-5.
5. Gideon P, Henriksen O, Sperling B, et al. Early time course of N acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke 1992;23:1566-72.
6. Van der knaap MS, Van der Grond J, Luyten PR, et al. 1H and 31P magnetic resonance spectroscopy of brain degenerative cerebral disorders. Ann Neurol 1992;31:202-11.
7. Chong WK, Sweeney B, Wilkinson ID, et al. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic and MR imaging findings. Radiology 1993;188:119-24.
8. Matthews PM, Francis G, Antel J, et al. Proton magnetic resonance spectroscopy for metabolic characterisation of plaques in multiple sclerosis. Neurology 1991;41:1251-6.
9. Miller DH, Austin SJ, Connelly A, et al. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis [letter]. Lancet 1991;337:58-9.
10. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
11. De Stefano N, Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-9.
12. Arnold DL, Matthews PM, Francis G, et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis:assessment of the load of disease. Magn Reson Med 1990;14:154-9.
13. Husted CA, Goodin S, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994;36:157-65.
14. Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385-91.
15. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121:103-13.
16. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118;1583-92.
17. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-22.
18. 1H Magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:736-42.
19. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990;40:1764-9.
20. Narayana PA, Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56-71.
21. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med 1989;10:135-44.
22. Dousset V, Grossman RI, Ramer KN, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterisation with magnetization transfer imaging. Radiology 1992;182:483-91.
23. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-7.
24. Adams RD, Victor M, Mancall EL.Central pontine myelinolysis; a hitherto undescribed disease occurring in alcoholic and malnourished patients. Archives of Neurology and Psychiatry 1959:154-72.
25. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
26. Frahm J, Merboldt KD, Hanicke W. Localised proton spectroscopy using stimulated echoes. J Magn Reson 1987;72: 502-8.
27. Frahm J, Michaelis T, Bruhn H, et al. Improvements in localised proton NMR spectroscopy of human brain, water suppression, short echo times and 1 ml resolution. J Magn Reson 1990;290:464-73.
28. 1H-MRS using water as an internal standard. Magn Reson Imaging 1993;11:107-18.
29. Grimaud J, Millar J, Thorpe JW, et al. Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:306-8.
30. Norton WT, Poduslo SE, Suzuki K. Subacute sclerosing leukoencephalitis. II. Chemical studies including abnormal myelin and an abnormal ganglioside pattern. J Neuropathol Exp Neurobiol 1966;25:582-97.
31. Frahm J, Bruhn H, Gyngell ML, et al. Localised proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989;11:47-63.
32. Wolff SD, Balaban RS. Magnetization transfer imaging: practical aspects and clinical applications. Radiology 1994; 192:593-9.
33. Silver NC, Barker GJ, MacManus DG, et al. Decreased magnetisation transfer ratio due to demyelination: a case of central pontine myelinolysis. J Neurol Neurosurg Psychiatry [letter] 1996;60:208-9.
34. Hiehle JF, Lenkinski RE, Grossman RI, et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med 1994;32:285-93.
35. Grossman RI, Lenkinski RE, Ramer KN, et al. Proton magnetic resonance spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 1992;13:1535-43.
36. Kimura H, Grossman RI, Lenkinski RE, et al. Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: correlative findings of active versus irreversible plaque disease. AJNR Am J Neuroradiol 1996;17:1539-47.
37. Lai HM, Davie CA, Gass A, et al. Serial magnetisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis. J Neurol 1997;224:308-11.
38. Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993;33:137-51.
39. Thorpe JW, Barker GJ, Jones SJ, et al. Quantitative MRI in optic neuritis: correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry 1995;59:487-92.
40. Lexa FJ, Grossman RI, Rosenquist AC. MR of Wallerian degeneration in the feline visual system: characterization by magnetization transfer rate with histopathologic correlation. AJNR Am J Neuroradiol 1994;15:201-12.